

Online Supplementary File 2

Cardiac rehabilitation delivery model for low-resource settings

Authors: Grace SL, Turk-Adawi KI, Contractor A, Atrey A, Campbell N, Derman W, Ghisi GLM, Oldridge N, Sarkar BK, Yeo TJ, Lopez-Jimenez F, Mendis S, Oh P, Hu D & Sarrafzadegan N.

References for Table 1

1. World Health Organization. Prevention Of Recurrent Heart Attacks and Strokes in Low and Middle Income Populations. Evidence-Based Recommendations for Policy Makers and Health Professionals. Geneva: WHO 2003.
2. Antunes-Correa LM, Kanamura BY, Melo RC, et al. Exercise training improves neurovascular control and functional capacity in heart failure patients regardless of age. *Eur J Prev Cardiol* 2012;19:822-9.
3. Chan C, Tang D, Jones A. Clinical outcomes of a cardiac rehabilitation and maintenance program for Chinese patients with congestive heart failure. *Disabil Rehabil* 2008;30:1245-53.
4. Digenio AG, Sim JG, Krige K, et al. The Johannesburg cardiac rehabilitation programme. *South African Medical Journal* 1991;79:183-7.
5. Ghashghaei FE, Sadeghi M, Rabiei K, et al N. Gender differences in risk factors of obese patients after cardiac rehabilitation program. *Iran J Nurs Midwifery Res* 2012;17:381-5.
6. Sadeghi M, Ghashghaei FE, Rabiei K, et al. Is there any difference between non-obese male and female in response to cardiac rehabilitation programs? *J Res Med Sci* 2012;17:787-91.
7. Sadeghi M, Ghashghaei FE, Rouhafza H. Comparing the effects of a cardiac rehabilitation program on functional capacity of obese and non-obese women with coronary artery disease. *ARYA Atheroscler* 2012;8:55-8.
8. Sadeghi M, Garakyaraghi M, Khosravi M, et al. The impacts of cardiac rehabilitation program on echocardiographic parameters in coronary artery disease patients with left ventricular dysfunction. *Cardiol Res Pract* 2013 (2013). <http://dx.doi.org/10.1155/2013/201713> (accessed 7 April 2015).

9. Sadeghi M, Garakyaraghi M, Taghavi M, et al. The impacts of cardiac rehabilitation program on exercise capacity, quality of life, and functional status of coronary artery disease patients with left ventricular dysfunction. *Rehabil Nurs* 2014;40:305-9.
10. Shabani R, Gaeini AA, Nikoo MR, et al. Effect of cardiac rehabilitation program on exercise capacity in women undergoing coronary artery bypass graft in Hamadan-Iran. *Int J Prev Med* 2010;1:247-51.
11. Soleimani A, Alidoosti M, Salarifar M, et al. Effect of cardiac rehabilitation program on heart rate recovery after percutaneous coronary intervention and coronary artery bypass grafting. *The Journal of Tehran University Heart* 2008;3:11-6.
12. Haddadzadeh M, Maiya A, Padmakumar R, et al. Effect of exercise-based cardiac rehabilitation on ejection fraction in coronary artery disease patients: a randomized controlled trial. *Heart Views* 2011;12:51-7.
13. Servantes DM, Pelcerman Al, Salvetti XM, et al. Effects of home-based exercise training for patients with chronic heart failure and sleep apnoea: a randomized comparison of two different programmes. *Clin Rehabil* 2012;26:45-57.
14. Dauchet LAP, Dallongeville J. Fruit and vegetable consumption and risk of stroke: a meta-analysis of cohort studies. *Neurology* 2005;65:1193-7.
15. Dauchet L, Amouyel P, Hercberg S, et al. Fruit and vegetable consumption and risk of coronary heart disease: a meta-analysis of cohort studies. *J Nutr* 2006;136:2588-93.
16. Pereira MA, O'Reilly E, Augustsson K, et al. Dietary fiber and risk of coronary heart disease: a pooled analysis of cohort studies. *Arch Intern Med* 2004;164:370-6.
17. Malik VS, Popkin BM, Bray GA, et al. Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. *Circulation* 2010;121:1356-64.
18. Hooper L, Summerbell DC, Thompson R, et al. Reduced or modified dietary fat for preventing cardiovascular disease. *Cochrane Database Syst Rev* 2011;7:CD002137 doi: 10.1002/14651858.CD002137.pub3.
19. Mozaffarian D, Renata Micha, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. *PLoS Med* 2010;7:e1000252 doi: 10.1371/journal.pmed.1000252.
20. World Health Organization. Guideline: Sodium Intake for Adults and Children. Geneva; WHO 2012.

21. Talati R, Sobieraj DM, Makanji SS, et al The comparative efficacy of plant sterols and stanols on serum lipids: a systematic review and meta-analysis. *J Am Diet Assoc* 2010;110:719-26.
22. Kumar MS, Sarma PS, Thankappan KR. Community-based group intervention for tobacco cessation in rural Tamil Nadu, India: a cluster randomized trial. *J Subst Abuse Treat* 2012;43:53-60.
23. Stead L, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. *Cochrane Database Syst Rev* 2012;11:CD000146. doi: 10.1002/14651858.
24. Woolf KJ, Zabad MN, Post JM, et al. Effect of nicotine replacement therapy on cardiovascular outcomes after acute coronary syndromes. *Am J Cardiol* 2012;110:968-70.
25. Jorenby D. Clinical efficacy of bupropion in the management of smoking cessation. *Drugs* 2002;62 (Suppl 2):25-35.
26. Jorenby D, Hays JT, Rigotti NA, et al. Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. *JAMA* 2006;296:56-63.
27. Etter J. Cytisine for smoking cessation: a literature review and a meta-analysis. *Arch Intern Med* 2006;166:1553-9.
28. West R, Zatonski W, Cedzynska M, et al. Placebo-controlled trial of cytisine for smoking cessation. *N Engl J Med* 2011;365:1193-200.
29. Sarrafzadegan N, Rabiei K, Kabir A, et al. Gender differences in risk factors and outcomes after cardiac rehabilitation. *Acta Cardiol* 2008;63:763-70.
30. Dehdari T, Heidarnia A, Ramezankhani A, et al. Effects of phase III cardiac rehabilitation programs on anxiety and quality of life in anxious patients after coronary artery bypass surgery. *J Tehran Heart Cent* 2007;2:207-12.
31. Kulcu DG, Kurtais Y, Tur BS, et al. The effect of cardiac rehabilitation on quality of life, anxiety and depression in patients with congestive heart failure. A randomized controlled trial, short-term results. *Eura Medicophys* 2007;43:489-97.
32. Poortaghi S, Safayian A, Baghernia A. General health improves with home-based cardiac rehabilitation program. *Saudi Med J* 2011;33:407-11.
33. Davidson KW, Bigger J, Burg MM, et al. Centralized, stepped, patient preference-based treatment for patients with post-acute coronary syndrome depression: CODIACS vanguard randomized controlled trial. *JAMA Intern Med* 2013;173:997-1004.

34. Whalley B, Rees K, Davies P, et al. Psychological interventions for coronary heart disease. *Cochrane Database of Syst Rev* 2011: CD002902 doi: 10.1002/14651858.CD002902.pub3.
35. Kovoor P, Lee AKY, Carrozzi F, et al. Return to full normal activities including work at two weeks after acute myocardial infarction. *Am J Cardiol* 2006;97:952-8.
36. Sarrafzadegan N, Rabiei K, Kabir A, et al. Changes in lipid profile of patients referred to a cardiac rehabilitation program. *Eur J Prev Cardiol* 2008;15:467-72.
37. Grundy SM, Arai H, Barter P, et al. An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia-full report. *J Clin Lipidol* 2014;8:29-60.
38. Lopez-Jimenez F, Simha V, Thomas RJ, et al. A summary and critical assessment of the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: filling the gaps. *Mayo Clin Proc* 2014;89:1257-78.
39. Gee ME, Campbell N, Sarrafzadegan N, et al. Standards for the uniform reporting of hypertension in adults using population survey data: recommendations from the World Hypertension League Expert Committee. *J Clin Hypertens* 2014;16:773-81.
40. Dasgupta K, Quinn RR, Zarnke KB, et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. *Can J Cardiol* 2014;30:485-501.
41. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens* 2013;31:1281-357.
42. Sanchez RA, Ayala M, Baglivo H, et al. Latin American guidelines on hypertension. *J Hypertens* 2009:905-22.
43. Fleg JL, Forman DE, Berra K, et al. Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association. *Circulation* 2013;128:2422-46.
44. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. *J Hypertens* 2014;32:3-15.
45. National Clinical Guidelines Centre Hypertension. The clinical management of primary hypertension in adults. *National Clinical Guideline Centre* 2004;1:1-310.

46. Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. *J Am Coll Cardiol* 2015;65:1998-2038.
47. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. *Circulation* 1995;92:1326-31.
48. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. *Circulation* 2007;115:2761-88.
49. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 2002;324:71-86.
50. Ferreira-González I, Marsal JR, Ribera A, et al. Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year. *J Am Coll Cardiol* 2012;60:1333-9.
51. Smith S, Benjamin E, Bonow R, et al. AHA/ACCF Secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. *Circulation* 2011;124:2458-73.
52. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. *Lancet* 2003;362:759-66.
53. Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. *Cochrane Database of Syst Rev* 2010;3: CD004371 doi: 10.1002/14651858.CD004371.pub3.